Intignus Biotech Pvt Ltd

Preeclampsia is a hypertensive disorder causing significant morbidity and mortality in pregnant women, unborn foetuses and newborns. This condition manifests symptomatically, and can be currently diagnosed only after 20 weeks of gestation. High blood pressure, proteinuria, and vital organ damage are common symptoms. As preeclampsia can strike quickly, potentially causing severe and immediate complications (such as seizures and organ failure that threaten both the health of the baby and mother) unless the pregnancy is induced, early and point of care screening and diagnostic tests are needed. Currently, there are no tests available for screening pregnant women to determine the risk of PE development. We have developed PEscreen, a screening test for all pregnant women which can predict preeclampsia development in the upcoming weeks of gestation based on circulating levels of a placenta specific preeclampsia biomarker. This test is to be performed when the women visit their gynaecologist during the fixed, routine check-ups.